Cholinesterase inhibitors are primarily used in the treatment of patients with mild to moderate Alzheimer's disease. Rivastigmine is a centrally selective cholinesterase inhibitor with a high selectivity for the hippocampus and cortex.([1]) A recent paper showed that in patients with Alzheimer's disease, treatment with high dosages of rivastigmine of 6-12 mg/day produced improvements in cognitive function and disease severity. [([2,3]) The most common adverse drug reactions associated with rivastigmine include nausea, vomiting and abdominal pain. These are mild to moderate, of short duration and diminish with a reduction in dosage. They commonly occur during the dosage titration phase and decrease during the maintenance phase. In this report, we present a case of melaena during therapy with rivastigmine in a patient with Alzheimer's disease.

Cholinesterase inhibitors are primarily used in the treatment of patients with mild to moderate Alzheimer's disease. Rivastigmine is a centrally selective cholinesterase inhibitor with a high selectivity for the hippocampus and cortex.([1]) A recent paper showed that in patients with Alzheimer's disease, treatment with high dosages of rivastigmine of 6-12 mg/day produced improvements in cognitive function and disease severity. [([2,3]) The most common adverse drug reactions associated with rivastigmine include nausea, vomiting and abdominal pain. These are mild to moderate, of short duration and diminish with a reduction in dosage. They commonly occur during the dosage titration phase and decrease during the maintenance phase. In this report, we present a case of melaena during therapy with rivastigmine in a patient with Alzheimer's disease.

Melaena following use of the cholinesterase inhibitor rivastigmine

Gareri P;Gallelli L;Russo E;De Sarro G
2005-01-01

Abstract

Cholinesterase inhibitors are primarily used in the treatment of patients with mild to moderate Alzheimer's disease. Rivastigmine is a centrally selective cholinesterase inhibitor with a high selectivity for the hippocampus and cortex.([1]) A recent paper showed that in patients with Alzheimer's disease, treatment with high dosages of rivastigmine of 6-12 mg/day produced improvements in cognitive function and disease severity. [([2,3]) The most common adverse drug reactions associated with rivastigmine include nausea, vomiting and abdominal pain. These are mild to moderate, of short duration and diminish with a reduction in dosage. They commonly occur during the dosage titration phase and decrease during the maintenance phase. In this report, we present a case of melaena during therapy with rivastigmine in a patient with Alzheimer's disease.
2005
Cholinesterase inhibitors are primarily used in the treatment of patients with mild to moderate Alzheimer's disease. Rivastigmine is a centrally selective cholinesterase inhibitor with a high selectivity for the hippocampus and cortex.([1]) A recent paper showed that in patients with Alzheimer's disease, treatment with high dosages of rivastigmine of 6-12 mg/day produced improvements in cognitive function and disease severity. [([2,3]) The most common adverse drug reactions associated with rivastigmine include nausea, vomiting and abdominal pain. These are mild to moderate, of short duration and diminish with a reduction in dosage. They commonly occur during the dosage titration phase and decrease during the maintenance phase. In this report, we present a case of melaena during therapy with rivastigmine in a patient with Alzheimer's disease.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12317/6947
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 11
social impact